The Evolving View of Coronary Artery Calcium: A Personalized Shared Decision-Making Tool in Primary Prevention.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical guidelines with no original human data
PubMed 31511792 · doi:10.1155/2019/7059806
What was done
This narrative review examines the 2018 American Heart Association and American College of Cardiology (AHA/ACC) cholesterol management guideline recommendations regarding coronary artery calcium (CAC) testing for primary atherosclerotic cardiovascular disease (ASCVD) prevention.
What was found
No experimental data or study-level effect sizes are reported in the abstract. The authors outline guideline-defined thresholds recommending CAC scoring for asymptomatic individuals at borderline (5% to 7.5%) and intermediate (7.5% to 20%) 10-year ASCVD risk. The review highlights that a CAC score of 0 indicates a group where intensive statin therapy is generally not beneficial, making lifestyle modification the primary recommendation.
Why it matters
CAC scoring provides an objective decision-making aid in borderline and intermediate-risk primary prevention, helping avoid unnecessary long-term statin therapy in low-risk individuals while focusing treatment on those with detectable calcification.
Limits
This is a narrative review without original clinical trial data, systematic search criteria, or pooled statistical analyses. All findings represent guideline committee interpretations and expert consensus rather than newly generated empirical evidence.
Cited by
- supports Clinical guideline committees state that if a patient has a coronary artery calcium score of zero, they do not need a statin.